Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901998 | 0.90 | HTR7 (0.37) | HRH3CYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL7959048 | 0.79 | CYP1A2 (0.39) | HRH3CYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL7959259 | 0.75 | KDM4E (0.43) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL7959344 | 0.74 | KDM4E (0.42) | CYP1A2CYP2D6CYP2C19KDM4EALDH1A1 | |
| SCHEMBL500010 | 0.71 | — | — | |
| SCHEMBL7958910 | 0.69 | CCR5 (0.40) | KDM4EALDH1A1SMN1; SMN2TDP1HTR7 | |
| SCHEMBL31287284 | 0.66 | TSHR (0.52) | KDM4EALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL22469662 | 0.66 | TSHR (0.52) | KDM4EALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL1802523 | 0.66 | DPP4 (0.33) | — | |
| SCHEMBL11550825 | 0.65 | PTPN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2621919-B1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2621919-A1 | PHENYLQUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | HRH3 1122/4885CYP1A2 863/4885CYP2D6 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.